Compare SHAZ & STTK Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
Current Price
| Metric | SHAZ | STTK |
|---|---|---|
| Founded | 2024 | 2016 |
| Country | United States | United States |
| Employees | N/A | N/A |
| Industry | EDP Services | Biotechnology: Pharmaceutical Preparations |
| Sector | Technology | Health Care |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 284.9M | 275.9M |
| IPO Year | N/A | 2020 |
| Metric | SHAZ | STTK |
|---|---|---|
| Price | $25.07 | $6.01 |
| Analyst Decision | | Buy |
| Analyst Count | 0 | 7 |
| Target Price | N/A | ★ $7.60 |
| AVG Volume (30 Days) | 143.7K | ★ 596.5K |
| Earning Date | 06-22-2026 | 03-05-2026 |
| Dividend Yield | N/A | N/A |
| EPS Growth | N/A | ★ 53.02 |
| EPS | ★ N/A | N/A |
| Revenue | N/A | ★ $1,000,000.00 |
| Revenue This Year | N/A | N/A |
| Revenue Next Year | N/A | N/A |
| P/E Ratio | N/A | ★ N/A |
| Revenue Growth | ★ N/A | N/A |
| 52 Week Low | $16.55 | $0.69 |
| 52 Week High | $31.95 | $6.27 |
| Indicator | SHAZ | STTK |
|---|---|---|
| Relative Strength Index (RSI) | 41.99 | 71.72 |
| Support Level | $16.75 | $1.85 |
| Resistance Level | $26.07 | N/A |
| Average True Range (ATR) | 2.93 | 0.42 |
| MACD | 0.69 | 0.09 |
| Stochastic Oscillator | 77.73 | 89.41 |
SharonAI Holdings Inc is a high-performance computing (HPC) company deploying large-scale energy and compute infrastructure, USA energy markets and infrastructure asset management. Its services include: Sovereign AI Australia, GPU-as-a-Service, SHARON AI Cloud, SHARON AI Private Cloud, Virtual Private Clusters, HPC Servers, SHARON AI Supercluster, GPU Fleet, Virtual Servers, Cloud Storage, AI Model Training, High-Performance Computing (HPC), and Video Encoding & Decoding. The company's products are: Sovereign AI Australia, GPU-as-a-Service, SHARON AI Cloud, SHARON AI Private Cloud, Virtual Private Clusters, HPC Servers, SHARON AI Supercluster, GPU Fleet, Virtual Servers, Cloud Storage, AI Model Training, High Performance Computing (HPC), and Video Encoding & Decoding.
Shattuck Labs Inc is a biotechnology company specializing in the development of potential treatments for inflammatory and immune-mediated diseases. It is developing a potentially first-in-class antibody for the treatment of inflammatory bowel disease (IBD) and other inflammatory and immune-mediated diseases. The company's expertise in protein engineering and the development of novel tumor necrosis factor (TNF) receptor therapeutics comes together in its main program, SL-325, which has the potential to be a first-in-class death receptor 3 (DR3) antagonist antibody. In addition, the company is developing SL-425, a half-life extended version of SL-325, and multiple other preclinical DR3-based bispecific antibodies, for the treatment of patients with IBD.